Archives
-
TAI-1: Hec1 Inhibition from Cell Origin to Assay
2026-09-17
TAI-1 is a potent Hec1 inhibitor whose mitotic mechanism can be studied more rigorously when cell state, RB1 biology, and assay design are considered together. This article connects TAI-1 pharmacology with new retinal organoid evidence while defining practical boundaries for cancer research interpretation.
-
Tropifexor (LJN452) for Reliable FXR Assays
2026-09-16
A scenario-based guide to using Tropifexor (LJN452), SKU BA3602, in FXR, viability, proliferation, and intestinal barrier experiments. It explains concentration planning, DMSO controls, interpretation limits, and practical criteria for selecting a research-grade small molecule.
-
NMDA for Excitotoxicity and RGC Research
2026-09-16
Use NMDA to create a controlled receptor-mediated injury stimulus for excitotoxicity research, calcium influx measurement, and oxidative stress assay development. A workflow built around fresh dosing, temporal sampling, and BMP4-GPX4 pathway readouts can connect neuronal injury phenotypes with retinal stem-cell and glaucoma model questions.
-
Q-VD(OMe)-OPh in Mechanism-Resolved Cell Death Assays
2026-09-14
Q-VD(OMe)-OPh enables causal caspase inhibition in apoptosis research rather than relying on viability measurements alone. This guide explains how to use it to distinguish apoptosis from ferroptosis and autophagy in resistant colorectal cancer models, while defining translational limits.
-
ATS-9R: Precision Gene Delivery for Adipose Research
2026-09-14
ATS-9R, or Adipocyte-targeting sequence-9-arginine, connects Prohibitin-directed tissue recognition with nona-arginine-mediated nucleic acid delivery. This evidence-led article explains the biology, validation strategy, practical parameters, competitive positioning, and translational limits that matter when designing adipose-targeted gene-silencing studies.
-
Q-VD(OMe)-OPh: Caspase Inhibition Guide
2026-09-11
Q-VD(OMe)-OPh is a broad-spectrum pan-caspase inhibitor for controlled apoptosis assays and cell-death mechanism studies. Its reported nanomolar activity, solvent compatibility, and low-cytotoxicity profile make it useful for apoptosis research, while its selectivity limits must be considered.
-
Palonosetron and CINV: Evidence and Research Design
2026-09-10
This review examines palonosetron hydrochloride as a long-acting 5-HT3 receptor antagonist for preventing chemotherapy-induced nausea and vomiting. Its main contribution is a translational comparison linking receptor pharmacology, delayed-emesis control, and clinical trial interpretation while emphasizing that pharmacologic differences matter only when they improve patient outcomes.
-
CFTRinh-172 in Reliable Epithelial Cell Assays
2026-09-10
This scenario-driven guide explains how CFTRinh-172 (SKU B1435) can help researchers separate CFTR chloride transport from cytotoxicity, trafficking, and assay-vehicle effects. It provides practical design, interpretation, storage, and vendor-selection guidance for epithelial cell and secretory-transport studies.
-
Pentoxifylline, Rolipram, and Macrophage NO
2026-09-09
The reference study showed that Pentoxifylline and rolipram suppress LPS/interferon-γ-induced macrophage nitric oxide production by elevating intracellular cAMP and reducing inducible nitric oxide synthase expression. Its integrated in vitro and in vivo design connects phosphodiesterase inhibition with macrophage regulation while clarifying the substantially greater potency of rolipram.
-
Brazilin and 3-MA in MGO-Induced Endothelial Injury
2026-09-08
The reference study identifies a DOHH/eIF5A hypusination–AMPK/mTOR axis through which brazilin limits methylglyoxal-induced endothelial autophagy and apoptosis. Its combined use of 3-MA, Compound C, DOHH inhibition, gene silencing, and db/db mice provides a mechanistic framework for interpreting autophagy inhibition in diabetic vascular injury research.
-
TH287: A Schedule-Aware MTH1 Assay Strategy
2026-09-07
TH287, a potent MTH1 inhibitor, offers a schedule-aware framework for studying oxidized nucleotide stress and cancer-cell radiosensitization. This article translates recent CRPC findings into rigorous assay design, readout selection, and evidence-aware interpretation.
-
NMDA (N-Methyl-D-aspartic acid) in Neurobiology
2026-09-07
NMDA (N-Methyl-D-aspartic acid) is a selective NMDA receptor agonist used to induce receptor-mediated excitatory stress in neuroscience experiments. Its direct ion-channel activation supports controlled excitotoxicity research, while a 2025 mouse glaucoma study used NMDA-associated injury to examine BMP4-GPX4 signaling and ferroptosis-related phenotypes.
-
Cell Counting Kit-8 (CCK-8) Plus Protocol
2026-09-05
Cell Counting Kit-8 (CCK-8) Plus provides a rapid WST-8 readout for estimating viable-cell activity in proliferation, cytotoxicity, and drug-response workflows. It should be calibrated for each cell model and interpreted cautiously when treatments alter cellular metabolism, because the signal is a dehydrogenase-dependent proxy rather than a direct cell count.
-
Viral RIPK3 Degradation and Necroptotic Inflammation
2026-09-04
Liu and colleagues identified a cowpox virus protein family that recruits host SCF ubiquitin-ligase machinery to drive RIPK3 degradation, thereby suppressing necroptosis and reshaping infection outcomes. The work provides a mechanistic framework for studying how viral control of ubiquitin-dependent protein turnover influences inflammation, replication, and pathogen–host evolution.
-
NMDA for Excitotoxicity Research: Workflow Tips
2026-09-02
Build controlled NMDA receptor activation models that connect calcium influx measurement with oxidative stress, neuronal injury, and ferroptosis-related readouts. This practical guide translates a retinal glaucoma study into assay design, dosing, controls, and troubleshooting decisions.